163 related articles for article (PubMed ID: 37926706)
21. WTAP-mediated m6A modification on circCMTM3 inhibits hepatocellular carcinoma ferroptosis by recruiting IGF2BP1 to increase PARK7 stability.
Chen S; Xia H; Sheng L
Dig Liver Dis; 2023 Jul; 55(7):967-981. PubMed ID: 36586770
[TBL] [Abstract][Full Text] [Related]
22. m
Hu B; Gao J; Shi J; Wen P; Guo W; Zhang S
Mol Carcinog; 2023 Oct; 62(10):1599-1614. PubMed ID: 37449789
[TBL] [Abstract][Full Text] [Related]
23. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma.
Gutschner T; Hämmerle M; Pazaitis N; Bley N; Fiskin E; Uckelmann H; Heim A; Groβ M; Hofmann N; Geffers R; Skawran B; Longerich T; Breuhahn K; Schirmacher P; Mühleck B; Hüttelmaier S; Diederichs S
Hepatology; 2014 May; 59(5):1900-11. PubMed ID: 24395596
[TBL] [Abstract][Full Text] [Related]
24. Long noncoding RNA NBAT1 suppresses hepatocellular carcinoma progression via competitively associating with IGF2BP1 and decreasing c-Myc expression.
Wei L; Ling M; Yang S; Xie Y; Liu C; Yi W
Hum Cell; 2021 Mar; 34(2):539-549. PubMed ID: 33387362
[TBL] [Abstract][Full Text] [Related]
25. A functional loop between YTH domain family protein YTHDF3 mediated m
Zhou R; Ni W; Qin C; Zhou Y; Li Y; Huo J; Bian L; Zhou A; Li J
J Exp Clin Cancer Res; 2022 Dec; 41(1):334. PubMed ID: 36471428
[TBL] [Abstract][Full Text] [Related]
26. METTL3/IGF2BP1/CD47 contributes to the sublethal heat treatment induced mesenchymal transition in HCC.
Fan Z; Gao Y; Zhang W; Yang G; Liu P; Xu L; Wang J; Yan Z; Han H; Liu R; Shu M
Biochem Biophys Res Commun; 2021 Mar; 546():169-177. PubMed ID: 33582561
[TBL] [Abstract][Full Text] [Related]
27. Long non-coding RNA GAS6-AS1 acts as a ceRNA for microRNA-585, thereby increasing
Ai J; Sun J; Zhou G; Zhu T; Jing L
Cell Cycle; 2020 Apr; 19(7):742-757. PubMed ID: 32089066
[TBL] [Abstract][Full Text] [Related]
28. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
[TBL] [Abstract][Full Text] [Related]
29. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m
Chen Y; Zhao Y; Chen J; Peng C; Zhang Y; Tong R; Cheng Q; Yang B; Feng X; Lu Y; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2020 Aug; 19(1):123. PubMed ID: 32772918
[TBL] [Abstract][Full Text] [Related]
30. A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA.
He J; Zuo Q; Hu B; Jin H; Wang C; Cheng Z; Deng X; Yang C; Ruan H; Yu C; Zhao F; Yao M; Fang J; Gu J; Zhou J; Fan J; Qin W; Yang XR; Wang H
Cancer Lett; 2019 May; 450():98-109. PubMed ID: 30790682
[TBL] [Abstract][Full Text] [Related]
31. IGF2BP1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner and promotes endometrial cancer progression.
Zhang L; Wan Y; Zhang Z; Jiang Y; Gu Z; Ma X; Nie S; Yang J; Lang J; Cheng W; Zhu L
Theranostics; 2021; 11(3):1100-1114. PubMed ID: 33391523
[No Abstract] [Full Text] [Related]
32. N
Wei H; Huang L; Lu Q; Huang Z; Huang Y; Xu Z; Li W; Pu J
J Hepatocell Carcinoma; 2023; 10():1991-2007. PubMed ID: 37954496
[TBL] [Abstract][Full Text] [Related]
33. Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation.
Lin XT; Yu HQ; Fang L; Tan Y; Liu ZY; Wu D; Zhang J; Xiong HJ; Xie CM
Elife; 2021 Nov; 10():. PubMed ID: 34779401
[TBL] [Abstract][Full Text] [Related]
34. N
Lu J; Ru J; Chen Y; Ling Z; Liu H; Ding B; Jiang Y; Ma J; Zhang D; Ge J; Li Y; Sun F; Chen D; Zheng S; Wu J
Clin Transl Med; 2023 Oct; 13(10):e1451. PubMed ID: 37877357
[TBL] [Abstract][Full Text] [Related]
35.
Yang Y; Wu J; Liu F; He J; Wu F; Chen J; Jiang Z
Stem Cells Dev; 2021 Nov; 30(22):1115-1125. PubMed ID: 34514861
[TBL] [Abstract][Full Text] [Related]
36. SNHG16 as the miRNA let-7b-5p sponge facilitates the G2/M and epithelial-mesenchymal transition by regulating CDC25B and HMGA2 expression in hepatocellular carcinoma.
Li S; Peng F; Ning Y; Jiang P; Peng J; Ding X; Zhang J; Jiang T; Xiang S
J Cell Biochem; 2020 Mar; 121(3):2543-2558. PubMed ID: 31696971
[TBL] [Abstract][Full Text] [Related]
37. YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma.
Hou J; Zhang H; Liu J; Zhao Z; Wang J; Lu Z; Hu B; Zhou J; Zhao Z; Feng M; Zhang H; Shen B; Huang X; Sun B; Smyth MJ; He C; Xia Q
Mol Cancer; 2019 Nov; 18(1):163. PubMed ID: 31735169
[TBL] [Abstract][Full Text] [Related]
38. miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL.
Chen L; Guan H; Gu C; Cao Y; Shao J; Wang F
Tumour Biol; 2016 Feb; 37(2):2497-507. PubMed ID: 26385772
[TBL] [Abstract][Full Text] [Related]
39. ANP32A promotes the proliferation, migration and invasion of hepatocellular carcinoma by modulating the HMGA1/STAT3 pathway.
Tian Z; Liu Z; Fang X; Cao K; Zhang B; Wu R; Wen X; Wen Q; Shi H; Wang R
Carcinogenesis; 2021 Apr; 42(3):493-506. PubMed ID: 33332531
[TBL] [Abstract][Full Text] [Related]
40. RHPN1-AS1 Drives the Progression of Hepatocellular Carcinoma via Regulating miR-596/IGF2BP2 Axis.
Fen H; Hongmin Z; Wei W; Chao Y; Yang Y; Bei L; Zhihua S
Curr Pharm Des; 2020; 25(43):4630-4640. PubMed ID: 31692433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
